May 1 (UPI) --Pharmaceutical giant Johnson & Johnson on Wednesday said it is taking steps to resolve a multibillion dollar, cancer-related lawsuit with thousands of individuals over claims that ...
J&J will buy Momenta Pharmaceuticals for roughly $6.5 billion in cash, paving the way for its Janssen unit to expand its efforts into autoimmune disease treatments. J&J will pay $52.50 for each ...
Johnson and Johnson reiterated in its statement on Wednesday, May 1, that “none of the talc-related claims against it have ...
Johnson & Johnson is proposing a $6.5 billion settlement to resolve thousands of lawsuits claiming its talc products caused ovarian cancer. J&J aims to settle the legal claims through a third ...
A subsidiary of Johnson & Johnson is now proposing to pay approximately $6.48 billion over 25 years as part of a settlement in ...
Benzinga - by Vandana Singh, Benzinga Editor. Wednesday, Johnson & Johnson (NYSE:JNJ) announced its intention to proceed with a $ ...
Johnson & Johnson Wants To Deal With Talc Lawsuit Overhang, Proposes $6.5B Settlement Package Mi Aktien New York: Anleger etwas erleichtert nach US-Zinsentscheid ...
NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (AMAM), in an all-cash merger deal for a total equity value of ...
Johnson & Johnson has added Israel to its Customer Connect order management website after questions rose over why it was excluded while "Palestine" was not. Through a bankruptcy filing of its ...
Johnson & Johnson’s MedTech division said Tuesday it plans to submit an application to the U.S. Food and Drug Administration ...